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Abstract
Background
Artemisinin-based combination therapies (ACTs) are the mainstay of the current treatment
of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spreading across
Southeast Asia. Dihydroartemisinin-piperaquine is one of the five ACTs currently recom-
mended by the World Health Organization. Previous studies suggest that young children
(<5 y) with malaria are under-dosed. This study utilised a population-based pharmacokinetic
approach to optimise the antimalarial treatment regimen for piperaquine.
Methods and Findings
Published pharmacokinetic studies on piperaquine were identified through a systematic lit-
erature review of articles published between 1 January 1960 and 15 February 2013. Individ-
ual plasma piperaquine concentration–time data from 11 clinical studies (8,776 samples
from 728 individuals) in adults and children with uncomplicated malaria and healthy volun-
teers were collated and standardised by the WorldWide Antimalarial Resistance Network.
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Data were pooled and analysed using nonlinear mixed-effects modelling. Piperaquine phar-
macokinetics were described successfully by a three-compartment disposition model with
flexible absorption. Body weight influenced clearance and volume parameters significantly,
resulting in lower piperaquine exposures in small children (<25 kg) compared to larger chil-
dren and adults (25 kg) after administration of the manufacturers’ currently recommended
dose regimens. Simulated median (interquartile range) day 7 plasma concentration was
29.4 (19.3–44.3) ng/ml in small children compared to 38.1 (25.8–56.3) ng/ml in larger chil-
dren and adults, with the recommended dose regimen. The final model identified a mean
(95% confidence interval) increase of 23.7% (15.8%–32.5%) in piperaquine bioavailability
between each piperaquine dose occasion. The model also described an enzyme maturation
function in very young children, resulting in 50% maturation at 0.575 (0.413–0.711) y of age.
An evidence-based optimised dose regimen was constructed that would provide pipera-
quine exposures across all ages comparable to the exposure currently seen in a typical
adult with standard treatment, without exceeding the concentration range observed with the
manufacturers’ recommended regimen. Limited data were available in infants and pregnant
women with malaria as well as in healthy individuals.
Conclusions
The derived population pharmacokinetic model was used to develop a revised dose regimen
of dihydroartemisinin-piperaquine that is expected to provide equivalent piperaquine expo-
sures safely in all patients, including in small children with malaria. Use of this dose regimen
is expected to prolong the useful therapeutic life of dihydroartemisinin-piperaquine by
increasing cure rates and thereby slowing resistance development. This work was part of
the evidence that informed the World Health Organization technical guidelines development
group in the development of the recently published treatment guidelines (2015).
Author Summary
Why Was This Study Done?
• Despite expansion of malaria prevention and treatment in the last decade, malaria still
kills around 1,200 people each day, mostly children below the age of five.
• Reduced drug exposure to one of the commonly used antimalarial drug combinations,
dihydroartemisinin-piperaquine, has been reported in small children.
• It is crucial to develop an optimised dose regimen that achieves similar drug exposure in
all patient groups, in order to give all patients an equal chance of cure.
What Did the Researchers Do and Find?
• Drug concentration–time data (8,776 piperaquine concentration measurements) from
728 individuals in 11 separate clinical trials were collated and pooled for an individual
participant data meta-analysis.
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• A pharmacokinetic model was developed to describe the pharmacological properties of
piperaquine, the expected variability between patients, and the influence of biologically
important covariates.
• Small children had a substantially lower piperaquine exposure after recommended dos-
ing regimens.
• The developed pharmacokinetic model was used to derive a new optimised dose
regimen.
What Do These Findings Mean?
• The proposed improved dose regimen of dihydroartemisinin-piperaquine is expected to
provide equivalent piperaquine exposures safely in all patients, including in small chil-
dren with malaria.
• An optimised dose regimen should prolong the useful therapeutic life of dihydroartemi-
sinin-piperaquine by increasing cure rates and thereby slowing resistance development.
Background
Malaria currently causes an estimated 1,200 deaths each day [1]. Most malaria-related deaths
occur in Africa in children under the age of 5 y. In endemic areas, young children lack sufficient
acquired immunity and are more likely to develop severe forms of the disease. Artemisinin-
based combination therapy (ACT) is the recommended first-line treatment for uncomplicated
Plasmodium falciparum malaria. The 3-d fixed-dose combination of dihydroartemisinin and
piperaquine is one of five ACTs currently recommended by the World Health Organization
(WHO) [2]. The rapidly eliminated dihydroartemisinin component has a very potent antima-
larial effect and eliminates the majority of the parasite biomass during the first 3 d of treatment
[3]. The partner drug, piperaquine, is a slowly eliminated antimalarial that kills the residual par-
asites that remain after two asexual life cycles of exposure to dihydroartemisinin, thereby pre-
venting recrudescent malaria. Piperaquine also prevents reinfections for approximately 1 mo
after treatment [4–11]. The principal determinant of the therapeutic response of a slowly elimi-
nated antimalarial drug is the duration for which the plasma (and thus free drug) level exceeds
the minimum inhibitory concentration, which is reflected by the area under the plasma concen-
tration–time curve, or its surrogate, the day 7 level [12].
Although there are several producers of dihydroartemisinin-piperaquine, three main
manufacturers are producing and distributing dihydroartemisinin-piperaquine in endemic
countries: Sigma-Tau Pharmaceuticals produces Eurartesim, registered with the European
Medicine Agency in 2012; Guilin Pharmaceutical produces D-Artepp; and Beijing Holley-
Cotec Pharmaceuticals produces Duo-Cotexin. Sigma-Tau’s recommendation is a target daily
dosage of 18 mg piperaquine phosphate per kilogram body weight across all age groups, with a
practical weight-based dosing schedule provided [13]. Beijing Holley-Cotec provides two
weight-based dosing schedules, one for children, with a target daily dosage of 16 mg/kg, and
one for adults [14,15]. Both manufacturers’ dosage recommendations are based on evidence
from the early stages of piperaquine development before there was extensive information on
the pharmacokinetic properties of piperaquine in young children (<5 y of age) and before
resistance to artemisinins was established. Artemisinin resistance results in lower fractional
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reductions in parasite numbers per asexual cycle, leaving a larger residual biomass of parasites
for the partner drug to remove. This increases the probability of recrudescence and drives the
spread of resistance. First artemisinin, and now piperaquine, resistance has emerged in Cambo-
dia [16–18]. Elsewhere the dihydroartemisinin-piperaquine combination has shown excellent
efficacy and tolerability, although young children treated with dihydroartemisinin-piperaquine
have a 3-fold greater risk of recrudescent malaria compared with older children and adults
[19–21]. Piperaquine is highly bound to plasma proteins (>98%), with a very large volume
of distribution (>100 l/kg), a low hepatic elimination clearance (<1.4 l/h/kg), and a conse-
quently long terminal plasma elimination half-life (estimates range from 18 to 28 d) [22–28].
The pharmacokinetic properties of piperaquine are affected by body weight, pregnancy, and age
[24,25,27,29,30]. A large quantity of co-administered fat enhances absorption significantly, par-
ticularly in healthy volunteers, whereas a small amount of fat does not [25,31,32]. Previous
reports on the pharmacokinetic properties of piperaquine in children are conflicting [22–
24,33]. The larger studies indicated that small children have an inadequate plasma exposure to
piperaquine after standard dosing, which led to a proposed increased dose regimen of dihy-
droartemisinin-piperaquine in order to achieve adequate exposures in small children [24,30].
Pharmacokinetic studies are often small and so have limited power to detect important covar-
iates. Provided the assay performances are comparable, pooling of individual participant data
from several studies increases the power to determine covariates with higher precision and accu-
racy. Nonlinear mixed-effects modelling for pharmacokinetic meta-analyses permits a unifying
structural, covariate, and statistical model to be developed [34]. Even with the best of tools, how-
ever, the heterogeneity of study designs and assay methods makes these analyses challenging.
The WorldWide Antimalarial Resistance Network (WWARN) is a unique data sharing
platform providing scientists and clinical investigators with an opportunity to share their data,
knowledge, and experience. The aim of this study was to use pooled individual participant
pharmacokinetic data from WWARN to characterise the pharmacokinetic properties of piper-
aquine, with a special focus on small children. Stochastic simulations from the final model
were used to develop an evidence-based optimised dose regimen based on maximum concen-
tration (as a measurement of toxicity) and piperaquine concentration at day 7 (as a measure-
ment of efficacy) [35].
Methods
Ethical Approval
Participating investigators agreed to the WWARN terms of submission [36], which ensure
that all data uploaded are anonymized and obtained with informed consent, and in accordance
with any laws and ethics committee approvals applicable in the country of origin. Ethics com-
mittee approval for the pooled analysis of individual participant data was granted by the
Oxford Tropical Research Ethics Committee.
Clinical Studies
All published pharmacology studies reported in PubMed, Google Scholar, Embase, Clinical-
Trials.gov, or conference proceedings were identified through a systematic literature review of
articles published between 1 January 1960 and 15 February 2013 according to PRISMA guide-
lines (Fig 1); the PRISMA checklist can be found in S1 PRISMA IPD Checklist. Principal
investigators were invited to contribute individual patient data to the WWARN repository as
part of a study group conducting a collaborative pooled analysis provided that their studies
met the following criteria: (i) prospective dihydroartemisinin-piperaquine study in patients
with uncomplicated P. falciparum infection or in healthy volunteers and (ii) validated measure
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of capillary and/or venous plasma piperaquine concentrations available. All data were up-
loaded to the WWARN repository and standardised using a methodology described in the
WWARN clinical and pharmacology data management and statistical analysis plans [37,38].
Study reports generated from the formatted datasets were sent back to investigators for clarifi-
cation and/or validation. Pharmacokinetic data from ten previously published clinical studies
and one unpublished (at the time) clinical study were contributed and used for modelling
[22,24,25,27,29,30,39–43]. Demographic data from each study are summarised in Table 1.
Study protocols for the studies were available in the original publication or on request from
the data contributor. Individual-patient-level data are available through WWARN (http://
www.wwarn.org). Requests for access will be reviewed by a Data Access Committee to ensure
that use of data is within the terms of consent and ethics approval. WWARN is registered with
the Registry of Research Data Repositories (http://re3data.org).
Pharmacokinetic Analysis
Plasma piperaquine concentrations (base form), transformed into their natural logarithms,
were analysed using nonlinear mixed-effects modelling implemented in NONMEM v7.3
(ICON Development Solutions) with the first-order conditional estimation method [45,46].
Perl-Speaks-NONMEM 3.5.3, R v2.14.2 (R Foundation for Statistical Computing) with the
Xpose package v4.3.5, and Piraña v2.6.0 were used for diagnostics and automation throughout
the modelling process [47–49].
Piperaquine was administered as piperaquine phosphate, which was converted to piperaquine
base with a scale factor of 57.7%. Two-, three-, and four-compartment disposition models were
evaluated with first-order absorption. The best performing model was used to evaluate the most
appropriate absorption model. First-order absorption with and without lag time and a more flexi-
ble transit absorption model with a fixed number (1–8) of transit compartments were investi-
gated. Inter-individual variability was added exponentially to all parameters according to Eq 1:
Pi ¼ yp  e
Zi;p ð1Þ
where Pi is the individual parameter estimate for the ith individual, θp is the population value of
Fig 1. Flowchart of the literature search.
doi:10.1371/journal.pmed.1002212.g001
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the investigated parameter, and ηi,p is the individual deviation from the population parameter
value for the ith individual. The η is drawn from a normal distribution with mean zero and vari-
ance ω2 (diagonal correlation matrix). The bioavailability was fixed to unity for the population,
though inter-individual variability of this parameter was allowed. Inter-occasion variability was
evaluated on absorption parameters (i.e., bioavailability and mean transit time) to allow variability
in rate and amount of piperaquine absorption between dosing occasions:
Pi;j ¼ yp  e
Zi;pþkj;p ð2Þ
where Pi,j is the individual estimate of the investigated parameter at the jth dosing occasion for
individual i. κj,p is the deviation from the population parameter value for the jth dose. The κ is
drawn from a normal distribution with mean zero and variance P2. The unknown variability in
concentration was described by an additive error on the individually predicted logarithmic con-
centrations (i.e., equivalent to an exponential error on non-transformed concentrations).
Body weight was evaluated by adding it as an allometric function to all clearance (power of
0.75) and volume of distribution (power of 1) parameters before any other covariates were
investigated, but an attempt was also made to estimate these exponents. The maturation pro-
cess of enzyme-dependent biotransformation pathways in infants and its effect on elimination
clearance in children below the age of 5 y was evaluated according to Eq 3:
CLi ¼ yCL 
AGEHilli
MFHill
50
þ AGEHilli
 eZi;CL ð3Þ
where CLi is the individual clearance parameter estimate for the ith individual, θCL is the popu-
lation value of the elimination clearance parameter, AGEi is the individual’s age, MF50 is the
age that results in 50% maturation, and Hill is the Hill coefficient describing the slope of the
maturation process.
Disease effect and gender (i.e., sex) were evaluated as proportional categorical covariates in
a subset of data to avoid false positive/negative relationships resulting from correlated covari-
ates. Disease effect was evaluated on all parameters in a dataset with only adult (>18 y of age)
male patients and healthy volunteers. The effect of gender was investigated on all parameters
in malaria-infected non-pregnant adults. Dosing occasion as a categorical covariate for absorp-
tion parameters was investigated using all the available data. Total daily dose per body weight
was also investigated as a linear covariate for absorption parameters. Substantial systematic
differences in matched venous and capillary plasma piperaquine concentrations have been
reported in a previous clinical study [50]. A proportional scaling factor between venous and
capillary concentrations was therefore estimated to allow fitting of all data simultaneously:
CCAP ¼ CVEN þ yS  CVEN ð4Þ
where CCAP is the individually predicted capillary concentration, CVEN is the individually pre-
dicted venous concentration, and θS is the population scale parameter between the two biologi-
cal matrices.
Model discrimination was based on the objective function value (OFV) proportional to −2
times the log likelihood of data. A reduction in OFV of 3.84 and 10.8 was considered signifi-
cant at p = 0.05 and p = 0.001, respectively, for a nested model with one degree of freedom dif-
ference. All covariates, except the allometric function of weight, were analysed in a step-wise
manner with a forward selection step (p = 0.05) and a stricter backward elimination step (p =
0.001). Model diagnostics and predictive performance were evaluated by goodness-of-fit plots
and simulation-based diagnostics (i.e., non-corrected, prediction-corrected, and variability-
corrected visual predictive checks), respectively [51]. Parameter precision was investigated by
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generating 1,000 resampled datasets, stratified by clinical study, in a bootstrap approach.
Parameter shrinkages were calculated [52] to determine the reliability of diagnostic plots.
Dose Optimisation
Stochastic simulations of the final mixed-effects model were performed to evaluate the expo-
sure to piperaquine after (i) the dose regimen recommended by Sigma-Tau, (ii) the dose regi-
men recommended by Beijing Holley-Cotec, and (iii) a putative optimised dose regimen, as
presented in Table 2 [24]. A total of 1,000 malaria-infected non-pregnant patients were simu-
lated per kilogram of body weight (range: 5 to 100 kg) and dose regimen. As a simple surrogate
of total exposure, predicted day 7 venous plasma piperaquine concentrations were compared
between simulations, while the maximum concentrations were compared as an indicator of
possible acute toxicity.
Results
Clinical Studies
A total of 11 different clinical studies were shared with WWARN, containing 8,776 plasma
piperaquine concentrations from 728 individuals that could be included in the pooled analysis
(Fig 1) [22,24,25,27,29,30,39–43]. Demographic data are presented in Table 1.
Table 2. Evaluated dose regimens for piperaquine simulations.
Dose Regimen Body
Weight (kg)
Number of
Tablets/Day
PQP/Day
(mg/kg)
Total Dosage (mg/kg) by Body Weight Group
All 5–15 kg >15 kg
Minimum Maximum Minimum Maximum Minimum Maximum
Sigma-Tau 38.4 80.1 39.9 73.8 38.4 80.1
5–6 0.25 13.3–16.0
7–12 0.5 13.3–22.9
13–23 1 13.9–24.6
24–35 2 18.3–26.7
36–74 3 13.0–26.7
75–100 4 12.8–17.1
Beijing Holley-Cotec 28.8 96 39.9 68.7 28.8 96
5–6 0.25 13.3–16.0
7–9 0.5 17.8–22.9
10–14 0.5* 15.2–21.3
15–19 1 16.8–21.3
20–39 2 16.4–32.0
40–100 3 9.60–24.6
Optimised 48 96 64 96 48 84.7
5–7 0.5 22.9–32.0
8–10 0.75 24.0–30.0
11–16 1 20.0–29.1
17–24 1.5 20.0–28.2
25–35 2 18.3–25.6
36–59 3 16.3–26.7
60–79 4 16.2–21.3
80–100 5 16.0–20.0
PQP/day is the total daily dosage of piperaquine phosphate (mg/kg). Minimum total dosage is the minimum total piperaquine dosage an individual receives
with each dose regimen. Maximum total dosage is the maximum total piperaquine dosage an individual receives with each dose regimen.
*One tablet given on the first day and half a tablet on the second and third day.
doi:10.1371/journal.pmed.1002212.t002
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Pharmacokinetic Properties of Piperaquine
Of the 8,776 samples included, 141 concentrations (1.74%) were measured to be below the
lower limit of quantification. These were the only measurements omitted from the analysis.
A three-compartment disposition model proved superior to a two-compartment disposition
model (p< 0.001). There was no further improvement from an additional fourth compartment
(p> 0.05). The absorption phase was described successfully by a transit compartment model
with two transit compartments (kA and kTR were assumed equal). This model proved superior
to all other tested absorption models (ΔOFV = −215). The addition of inter-individual variabil-
ity in relative bioavailability improved the model fit significantly (p< 0.001). The final struc-
tural model is presented in Fig 2. Inter-individual variability was retained on all parameters
(except inter-compartment clearance), and inter-occasion variability was significantly associ-
ated with relative bioavailability (p< 0.001) and mean transit time (p< 0.001).
Body weight as a fixed allometric function on all clearance and volume of distribution
parameters improved the fit of the model significantly (ΔOFV = −419). Estimating the expo-
nent on elimination clearance did not result in a significant drop in OFV (p> 0.001) com-
pared to using a fixed exponent, and the estimated exponent was similar to the fixed value.
A categorical disease effect had a significant impact on elimination clearance, mean transit
time, and central volume of distribution in the forward selection step (p< 0.05) and could be
retained on mean transit time and elimination clearance in the backward elimination step
(p< 0.001). However, during antimalarial treatment the patient usually recovers from the dis-
ease, so a disease effect on pharmacokinetics would be present only during the early assess-
ments (day 1–3). Attempts to model a time-dependent disease effect failed, probably because
of the low number of healthy volunteers (n = 50; 6.87%), of whom only 14 were dosed more
than once. Thus, this covariate effect was not retained in the final model. Similarly, an explor-
atory analysis showed that disease could also have an effect on relative bioavailability, resulting
in an increase in the exposure to piperaquine in healthy volunteers compared to patients.
Fig 2. A graphical overview of the final piperaquine population pharmacokinetic model. kTR is the absorption transit rate constant. CL is the
elimination clearance. VC is the volume of distribution of the central compartment. VP1 and VP2 are the volumes of distribution of the first and second
peripheral compartments, respectively. Q1 and Q2 are the inter-compartment clearances for the first and second peripheral compartments, respectively.
F is the relative oral bioavailability.
doi:10.1371/journal.pmed.1002212.g002
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However, the disease effect was not retained in the final analysis, again because of the low
number of healthy individuals. This needs to be addressed in future studies.
A 24% increase (p< 0.001) in relative bioavailability was observed between dose occasions,
whereas the total daily milligram/kilogram dosage did not influence absorption. This finding
is likely to be related to the recovery from malaria illness (and also increasing food intake) dur-
ing the 3 d of treatment [25,27], as the systematic dose-occasion effect was estimated as close
to zero in healthy volunteers. However, this covariate effect was not separated for patients and
healthy volunteers in the final model due to the small number of healthy volunteers who had
been dosed more than once (n = 14). Gender was found to affect the mean transit time signifi-
cantly among malaria-infected non-pregnant adults, but this covariate relationship could not
be retained in the more stringent backward step. Inclusion of a maturation factor produced
only a minor improvement in model fit (ΔOFV = −3.29) among children below 5 y of age.
However, inclusion of this covariate resulted in an estimated enzymatic maturation that
reflected the biological maturation of infants’ piperaquine biotransformation pathways; there-
fore, this factor was included in the final model.
Parameter estimates were reliable, with small relative standard errors (Table 3). Predicted
secondary pharmacokinetic parameters (i.e., elimination half-life, maximum concentration,
time to maximum concentration, total exposure, and day 7 plasma concentration) obtained
from the final model are presented in Table 3. Calculated η shrinkages were high due to the
sparseness of data in some of the individual studies, but the calculated ε shrinkage was low
(14.6%). Goodness-of-fit diagnostics and the prediction-corrected visual predictive check
(n = 2,000) demonstrated that the model described the observed data well (Figs 3 and 4). The
visual predicted check showed a small model misspecification for capillary versus venous
plasma concentrations, but overall the diagnostics supported using the developed model for
stochastic simulations and dose optimisations.
Dose Optimisation
The derived pharmacokinetic model predicted lower plasma piperaquine exposures in small
children (5–24 kg) and adults with body weight between 60 and 75 kg (or between 60 and 100
kg if following the dose recommendation from Beijing Holley-Cotec) compared to other adult
patients after dihydroartemisinin-piperaquine administration following the manufacturers’
recommended dose regimens. Simulated median (interquartile range) day 7 plasma concen-
tration was 29.4 (19.3–44.3) ng/ml in small children (<25 kg) compared to 38.1 (25.8–56.3)
ng/ml in larger children and adults (25 kg), with Sigma-Tau’s recommended dose regimen.
The revised dose regimen proposed here is expected to achieve predicted exposures at all body
weights comparable to that currently seen in a typical adult after appropriate standard treat-
ment (Table 2; Fig 5). Simulated maximum plasma piperaquine concentrations after manufac-
turers’ dosing and the new optimised dose regimen are presented in Fig 5. The minimum
and maximum piperaquine dosages of the three evaluated dose regimens are summarised in
Table 2. It is important to note that the predicted maximum plasma piperaquine concentra-
tions with the optimised regimen (upper 75th percentile of approximately 600 ng/ml) are not
higher than those observed with the manufacturers’ regimens.
Discussion
This study developed and validated a population pharmacokinetic meta-model to describe the
pharmacological properties of piperaquine and the influence of demographic and clinical
covariates. Body weight influenced clearance and volume parameters significantly, resulting in
lower piperaquine exposures in small children compared to larger children and adults after
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administration of the manufacturers’ currently recommended dose regimens. The final model
was used to develop a revised dose regimen of dihydroartemisinin-piperaquine that is expected
to provide therapeutic piperaquine exposures safely in all patients, including in small children
with malaria. This could improve the treatment of malaria in small children.
Dihydroartemisinin-piperaquine is an excellent fixed-dose ACT that has shown consis-
tently good efficacy in patients with uncomplicated P. falciparum malaria infection [4–8], but
cumulative evidence shows that dosing could be improved [19]. Under-dosing increases the
Table 3. Final parameter estimates describing piperaquine population pharmacokinetics.
Parameter Population Estimatea [%RSEb]
or Median (Minimum–Maximum)
95% CIb Coefficient of
Variation
for IIV/IOVa [%RSEb]
95% CIb Shrinkage
(Percent)a
CL/F (l/h) 55.4 [4.22] 51.2–60.6 27.9 [7.43] 23.7–31.7 38.1
VC/F (l) 2,910 [6.98] 2,540–3,340 67.0 [15.5] 49.7–89.4 46.9
Q1/F (l/h) 310 [8.03] 266–366 — — —
VP1/F (l) 4,910 [5.85] 4,390–5,510 24.0 [44.2] 1.35–40.4 71.4
Q2/F (l/h) 105 [4.98] 95.1–115 23.6 [15.6] 16.2–30.2 55.7
VP2/F (l) 30,900 [4.79] 28,300–
34,200
34.7 [7.21] 29.6–39.4 46.2
MTT (h) 2.11 [4.54] 1.94–2.30 38.0 [15.8]/46.4 [9.36] 26.7–50.3/38.6–
55.1
59.1/71.3
Number of transit
compartments
2 fix — — — —
F (percent) 100 fix — 41.4 [8.65]/53.5 [6.69] 34.0–48.2/46.1–
60.2
31.1/59.7
RUV 0.115 [3.43] 0.108–0.123 — — 14.6
Covariate relationships
Scale (percent) 106 [7.24] 91.7–122 — — —
MF50 (years) 0.575 [13.6] 0.413–0.711 — — —
HillMF 5.51 [29.6] 3.22–9.95 — — —
DoseF (percent) 23.7 [17.8] 15.8–32.5 — — —
Secondary parameters
CMAX (ng/ml) 248 (24.3–1,070)
TMAX (h) 3.49 (1.13–10.0)
T1/2 (d) 22.5 (9.15–52.3)
AUC1 (h × ng/ml) 28,800 (2,650–116,000)
Day 7 concentration (ng/ml) 28.1 (2.35–115)
Population estimates are given for a “typical” adult patient weighting 54 kg with acute falciparum malaria. CL/F is the apparent elimination clearance. Vc/F is
the apparent volume of distribution of the central compartment. Q1/F and Q2/F are the inter-compartment clearances between the central and the peripheral
compartments. VP1/F and VP2/F are the apparent volumes of distribution of the peripheral compartments. MTT is the mean transit time of the absorption.
Number of transit compartments is the number of transit compartments used in the absorption model. F is the relative bioavailability. RUV is the variance of
the unexplained residual variability. Scale is the difference between venous and capillary predictions. MF50 is the maturation age (in years) to reach 50% of
the full elimination clearance. HillMF is the Hill function in the maturation equation, with an upper limit of 10. DoseF represents the increase in relative
bioavailability between each dosing occasion. CMAX is the maximum concentration. TMAX is the time after dose to reach the maximum concentration. T1/2 is
the terminal elimination half-life. AUC1 is the area under the concentration–time curve from time 0 to infinity. Day 7 concentration is the venous plasma
concentration at day 7 after dosing. Coefficients of variation for inter-individual variability (IIV) and inter-occasion variability (IOV) were calculated as 100 ×
(evariance − 1)1/2. Relative standard errors (%RSE) were calculated as 100 × (standard deviation/mean). The 95% confidence intervals are given as the 2.5 to
97.5 percentiles of bootstrap estimates. Secondary parameters were calculated after the last dose.
aBased on population mean values from NONMEM.
bBased on 658 successful stratified bootstrap runs (out of 1,000).
doi:10.1371/journal.pmed.1002212.t003
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risk of treatment failure and therefore drives the development of resistance. Piperaquine
resistance developed in China, where piperaquine monotherapy was used for prevention
and treatment between 1978 and 1994, and has emerged again recently in Cambodia on a
background of artemisinin resistance [53–55]. To maximise its therapeutic lifespan, it is
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Fig 3. Basic goodness-of-fit plots for the final piperaquine model. Observed plasma piperaquine concentrations (from 11 clinical studies)
plotted against population predicted concentrations (A) and against individual predicted concentrations (B). Conditional weighted residuals plotted
against population prediction (C) and time (D). The solid line is the identity line, and the dashed line is the locally weighted least squares regression
line.
doi:10.1371/journal.pmed.1002212.g003
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essential to optimise dihydroartemisinin-piperaquine recommended dose regimens, which
would lower the risk of treatment failure and reduce the selective pressure for the develop-
ment of resistance. The present study used a pooled pharmacokinetic modelling approach
Fig 4. Prediction-corrected visual predictive check of the final population pharmacokinetic model of piperaquine. Based on 2,000 stochastic
simulations. The insert shows the first 25 h after dosing. Open circles represent the observations, and solid lines represent the 5th, 50th, and 95th percentiles
of the observed data. The shaded areas represent the 95% confidence intervals around the simulated 5th, 50th, and 95th percentiles.
doi:10.1371/journal.pmed.1002212.g004
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to evaluate dihydroartemisinin-piperaquine treatment and presents an optimised dose regi-
men that should improve the treatment of uncomplicated P. falciparum malaria.
A large WWARN pooled analysis of the clinical efficacy of dihydroartemisinin-piperaquine
in 7,072 patients enrolled in 26 studies highlighted a significant risk of recrudescent malaria in
young children (1–5 y of age) [19]. Younger children typically have the highest treatment failure
rates in meta-analyses of antimalarial treatments [19,21,56,57], usually attributed to relative lack
of immunity [20]. But lower drug exposure is another possible contributor. The previously pub-
lished pooled analysis demonstrated that the milligram/kilogram piperaquine dosage adminis-
tered was a significant predictor of treatment failure, with the risk of recrudescence increased
by 13% (95% CI 5.0%–21%) for every 5-mg/kg decrease in dosage on day 42 [19]. Previous
clinical studies as well as pharmacokinetic-pharmacodynamic modelling show that children
achieved a lower plasma exposure to piperaquine, compared to adults, after equivalent weight-
based (mg/kg) piperaquine dosage [24,30,35]. Taken together, these findings suggest the need
to increase dose regimens of dihydroartemisinin-piperaquine for small children.
Several studies have investigated the pharmacokinetic properties of piperaquine [6,10,23–
25,27,29,30,32,35,40,58–60]. However, the present study is, to our knowledge, the largest anal-
ysis to date, incorporating data from 8,776 pharmacokinetic samples from 728 individuals
from different target populations and continents. Our results can be used to inform evidence-
based optimised treatment in vulnerable young children with malaria, who account for an esti-
mated 78% of malaria-related deaths [1].
Pharmacokinetics of Piperaquine
A three-compartment disposition model with a transit compartment absorption model was
found to describe the pooled data adequately, which is in accordance with other recent studies
[24,25,27,29,30]. Inter-occasion (within-individual) variability had a significant impact on
both relative bioavailability and the mean transit time of the absorption, indicating a large
degree of variability not just among patients but also between dose occasions for a specific
Fig 5. Stochastic simulations of dose regimens. Maximum plasma piperaquine concentration (A–C) and day 7 plasma piperaquine concentration
(D–F) after Sigma-Tau’s recommended dosing (left panels), Beijing Holley-Cotec’s recommended dosing (middle panels), and the revised dose
regimen (right panels). Circles represent the median values, and vertical lines represent the 25th to 75th percentiles of simulated concentrations. The
dashed line indicates the previously defined venous plasma piperaquine day 7 concentration threshold value for therapeutic success of 30 ng/ml [35].
doi:10.1371/journal.pmed.1002212.g005
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patient. The final model showed satisfactory goodness-of-fit diagnostics and high precision in
parameter estimates. Estimated parameters were also comparable to those found in previous
studies [22,24,25,27,29]. The visual predictive check showed a small model misspecification
for the capillary versus venous plasma data, probably because capillary measurements were
performed only in studies of children with malaria, whereas the overall model is based on a
more diverse dataset. The model simulation therefore included more variability compared to
the observed data.
In agreement with previous studies [25,27], piperaquine absorption in patients with malaria
could be characterised further with a categorical covariate that increased the relative bioavail-
ability by 24% with each subsequent dose within a single course of treatment. This increase in
relative bioavailability may result from the improved gastrointestinal function and food intake
that accompanies clinical recovery. However, a disease effect on bioavailability could not be
evaluated given the few healthy volunteers (n = 14) who received more than one dose.
Most drug measurement data in children were based on capillary samples, compared to
venous plasma sampling in adult patients. A constant scale factor to convert between capillary
and venous plasma piperaquine measurements was therefore required to allow simultaneous
modelling of all individual patient data. The estimated capillary piperaquine concentrations were
106% higher than venous piperaquine concentrations, which is a greater difference than that
reported previously [58]. However, this conversion factor resulted in a good description of both
venous and capillary observations. An additional advantage of a simultaneous approach is that
the model can be used to predict drug exposures from any sampling technique and therefore
enables literature comparisons. The exact mechanism underlying this matrix-dependent differ-
ence cannot be elucidated from the data pooled in this analysis and needs further evaluation.
Metabolic enzymes mature during the first years of life in a way that cannot be explained by
an allometric function of body weight [61]. Most hepatic enzymes reach 70% to 100% matura-
tion during the first 12 mo of life [62]. Sambol et al. investigated age as a nonlinear covariate
(in addition to weight) and identified that, both covariates taken together, 6-mo-old infants
have approximately half the clearance of 2-y-old children [30]. To investigate this further, the
present study assessed age as a maturation function on piperaquine elimination clearance. The
inclusion of a maturation function improved the model fit. Although the improvement was
not statistically significant, the factor was kept in the final model to reflect the known changes
in biotransformation pathways that occur as the infant grows. More information is needed on
piperaquine disposition in the first 2 y of life.
A malaria disease effect was investigated but not retained in the final model given the few
healthy volunteers who received more than one dose (n = 14). However, the preliminary
results suggest that healthy patients have higher maximum concentrations and higher expo-
sures to piperaquine. This is an important caveat to the revised dosing recommendations—
they apply to the treatment of malaria. More information is needed on the pharmacokinetic
properties of 3-d dihydroartemisinin-piperaquine regimens in healthy individuals. This is par-
ticularly important as dihydroartemisinin-piperaquine is also being used in mass treatment
campaigns where most of the recipients are healthy.
Pregnancy was not evaluated in this analysis, since only 4.9% (n = 36) of the patients in the
study population were pregnant. However, pregnancy is expected to have a limited influence
on the pharmacokinetic model presented here. Separate pharmacokinetic evaluations of the
two studies that included pregnant women concluded that there were no differences in total
piperaquine exposures between pregnant and non-pregnant patients [27,29].
Young children in areas of high malaria transmission are at increased risk of developing
life-threatening severe malaria. Indeed, most of the deaths from malaria occur in African chil-
dren. Partially protective immunity that also boosts parasite elimination after treatment only
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develops after repeated infections. It is important that children receive effective treatments
at the doses needed to provide adequate exposure to all antimalarial drug components, but
particularly the artemisinin partner in the case of an ACT. Sub-therapeutic exposure also
increases the risk of drug resistance. The Sigma-Tau-recommended piperaquine dosage targets
a daily dosage of 18 mg/kg, with a range between 13 and 27 mg/kg at different body weights
(Table 2), while the dosage recommended by Beijing Holley-Cotec ranges from 9.6 to 32 mg/
kg. A constant weight-based (mg/kg) dosage target would be appropriate only if there were a
linear relationship between drug exposure and body weight, but physiological processes do not
scale linearly with body weight [30,61,63]. Body weight has been identified as an important
predictor of piperaquine exposure in previous studies [22,24,25,29], as confirmed in this study.
Consequently, children achieve a lower drug exposure compared to adults after a standard tar-
get daily dosage of 18 mg/kg, which increases their risk of treatment failure and could shorten
the useful therapeutic life of dihydroartemisinin-piperaquine [19]. This has potentially impor-
tant consequences for therapeutic outcome and the development of drug resistance. It likely
contributes to the>3-fold higher risk of recrudescence observed in children aged 1–5 y (haz-
ard ratio 3.71; 95% CI 1.66–8.26; p = 0.002) compared to patients >12 y of age [19]. Conse-
quently, in order to achieve exposure similar to that of adults, small children need higher doses
of piperaquine than currently recommended by the manufacturers.
Dose Optimisation
The pooled analysis presented here is, to our knowledge, the largest pharmacokinetic analysis
of piperaquine to date and incorporates data collected in phase III clinical trials and post-mar-
keting studies in a large variety of populations, resulting in a greater power to identify impor-
tant pharmacokinetic differences between key target populations. The final model showed
adequate predictive performance, demonstrating its suitability for dose optimisation simula-
tions. The final pharmacokinetic model was therefore used to simulate piperaquine exposures
and maximum piperaquine concentrations at different body weights using the dose regimens
recommended by the manufacturers (Sigma-Tau and Beijing Holley-Cotec) and was used to
develop an evidence-based improved dose regimen for small children.
Our simulations (Fig 5) show that both small children and adults with body weights
between 60 and 75 kg for the Sigma-Tau–recommended dose regimen (or between 60 and 100
kg for the Beijing Holley-Cotec–recommended dose regimen) achieve lower plasma pipera-
quine exposures than typical adult patients (35–65 kg) with acute falciparum malaria after
standard dosing (Table 2). The revised dosing scheme (Table 2) is predicted to achieve equiva-
lent plasma piperaquine exposures in all patient groups, including small children and larger
adults, without risking higher maximum piperaquine concentrations (Fig 5). A previously
pooled efficacy analysis of dihydroartemisinin-piperaquine treatment [19] showed that a total
minimum piperaquine dosage of 59 mg/kg would result in successful treatment in 95% of
small children. Our revised dose scheme proposes a total minimum dosage of 64 mg/kg for
children weighing 5–15 kg (Table 2), compared to the minimum dosage of 40 mg/kg recom-
mended by the manufacturers. This adjustment would ensure similar plasma piperaquine
exposure across all weight groups and, most importantly, would improve the treatment of
small children.
Most ACTs have a target artesunate dosage of 4 mg/kg/d according to WHO guidelines for
the treatment of malaria. This corresponds to a dihydroartemisinin dosage of 2.96 mg/kg/d
(based on molar equivalents). However, the current manufacturer-recommended dihydroarte-
misinin dosage ranges between 1.62 and 3.33 mg/kg/d for Sigma-Tau, and between 1.20 and
4.00 mg/kg/d for Beijing Holley-Cotec, giving the lowest dosage of the artemisinin component
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of all WHO-recommended ACTs. As dihydroartemisinin-piperaquine is a fixed-dose combi-
nation, the increased piperaquine doses recommended by this analysis will also increase the
dihydroartemisinin dosage, while remaining within the 2–10 mg/kg target range recom-
mended by WHO. Increasing both dihydroartemisinin and piperaquine concentrations
should contribute to a more effective therapy by reducing the residual parasite biomass
remaining on day 3, and reduce the risk of recrudescence and reinfection, thereby potentially
prolonging the useful therapeutic life of dihydroartemisinin-piperaquine.
Piperaquine prolongs ventricular repolarisation, and this is reflected in electrocardio-
graphic QT prolongation. Manning et al. [64] stopped a recent study in healthy volunteers
given a 50% higher than recommended daily dose of piperaquine for 2 d because four volun-
teers had potentially unsafe QT prolongation (>500 ms). However, that study used the auto-
mated electrocardiograph reading, mostly likely resulting in a reported QU interval instead of
the correct manual QT reading, which would be substantially shorter. Furthermore, increasing
the piperaquine dose by 50% in these healthy volunteers resulted in very high maximum
plasma piperaquine concentrations, with a mean value of 1,750 ng/ml [64], compared to a pre-
dicted median maximum concentration of 310 ng/ml following the suggested optimised dose
regimen (Fig 5). Small children receiving higher body-weight-based daily doses of pipera-
quine, after dose adjustment, are not expected to achieve higher maximum piperaquine con-
centrations than a typical non-pregnant adult patient given the manufacturer’s recommended
dose regimen (Fig 5). Thus, maximum plasma piperaquine concentrations after optimised
dosing are not expected to increase the risk of cardiac adverse events. However, the safety and
efficacy of this suggested revised dosing will need to be evaluated prospectively. Such prospec-
tive studies could also assess whether more pragmatic dose regimens with fewer body weight
bands could be achieved safely.
In the context of antimalarial drug registration for uncomplicated P. falciparum malaria,
patients recruited for phase II or phase III trials usually exclude important sub-populations
such as infants, pregnant women, and patients with co-morbidities (e.g., malnutrition, co-
infections). Thus, these sub-populations are unlikely to be represented in sufficient numbers
to draw a conclusion on their optimal dosing at the time of the initial registration of the drug
with a medicines regulatory authority. Pooled analyses of individual patient data accumulated
in the post-marketing phase are needed to allow dose optimisation for such vulnerable target
population groups, as these are the populations that carry the highest malaria morbidity and
mortality rates.
However, limited data were available in infants (1 y of age), pregnant women with
malaria, patients with co-morbidities, and healthy individuals for this pooled meta-analysis.
Thus, the pharmacological properties of piperaquine could not be assessed reliably in these
groups within the present analysis. Prospective pharmacological studies are urgently needed to
address potential differences in these sub-groups. Other study limitations are the lack of gen-
eral safety data, and the lack of data from large monotherapy piperaquine trials performed in
China between 1978 and 1994.
In conclusion, suboptimal plasma piperaquine exposures in small children given the cur-
rent manufacturers’ recommended dose regimens were confirmed in this pooled pharma-
cokinetic analysis. In addition, low exposure in adults with body weights of 60–100 kg
(depending on dose regimen) was also detected. Pharmacokinetic analysis was used to
derive an optimised antimalarial dose regimen. It is essential that currently used antimalar-
ial treatments are optimised in the post-registration phase so that all patient groups achieve
similar drug exposures, and thus an equal chance of being cured. This optimisation would
also reduce the selective pressure for the development of resistance, thus slowing the devel-
opment of drug resistance and prolonging the useful therapeutic life of dihydroartemisinin-
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piperaquine. It is essential that currently available antimalarials remain effective until novel
treatments can be produced to overcome artemisinin resistance. This evidence-based
improved dose regimen has been adopted by WHO in their recently published guidelines
for the treatment of malaria [2].
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